TOBI®: MORE THAN A DECADE OF USE1

A well-established record of efficacy and safety


  • TOBI is the only inhaled Pa treatment available for more than a decade that helps improve lung function and reduce hospital days in patients with CF.1,2
  • With proven efficacy, safety, and tolerability, TOBI continues to help CF patients fight Pa in the lungs1-3
  • The Cystic Fibrosis Pulmonary Guidelines report a "level A" recommendation for the use of inhaled tobramycin4
  • CF Pulmonary Guidelines are based on available evidence of efficacy and safety4
  • The recommendation of inhaled tobramycin is based on a review of 6 studies with a total of 679 patients. Of those, 520 (76%) were included in the TOBI pivotal studies4
  • TOBI is a special form of tobramycin that is inhaled. It is the only tobramycin solution approved by the FDA for inhalation1

There is only one TOBI

TOBI is formulated specifically for inhalation.

lady
 

More than a decade of use treating Pseudomonas aeruginosa in Cystic Fibrosis.

 
 
Important Safety Information full Prescribing Information www.fda.gov/medwatch

References:

  • TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
  • Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
  • Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120:107S-113S.
  • Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-969.
  • Pai VB, Nahata MC. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol. 2001;32:314-327.
  • US Food and Drug Administration. Report: limited FDA survey of compounded drug products. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm. Accessed September 1, 2010.